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Abstract
Invasion of hepatocytes by Plasmodium sporozoites is a prerequisite for establishment of a malaria infection, and thus
represents an attractive target for anti-malarial interventions. Still, the molecular mechanisms underlying sporozoite
invasion are largely unknown. We have previously reported that the tetraspanin CD81, a known receptor for the hepatitis C
virus (HCV), is required on hepatocytes for infection by sporozoites of several Plasmodium species. Here we have
characterized CD81 molecular determinants required for infection of hepatocytic cells by P. yoelii sporozoites. Using CD9/
CD81 chimeras, we have identified in CD81 a 21 amino acid stretch located in a domain structurally conserved in the large
extracellular loop of tetraspanins, which is sufficient in an otherwise CD9 background to confer susceptibility to P. yoelii
infection. By site-directed mutagenesis, we have demonstrated the key role of a solvent-exposed region around residue
D137 within this domain. A mAb that requires this region for optimal binding did not block infection, in contrast to other
CD81 mAbs. This study has uncovered a new functionally important region of CD81, independent of HCV E2 envelope
protein binding domain, and further suggests that CD81 may not interact directly with a parasite ligand during Plasmodium
infection, but instead may regulate the function of a yet unknown partner protein.
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Introduction
Malaria remains the most important parasitic human disease,
responsible for millions of deaths each year. Plasmodium infection is
initiated by the inoculation of sporozoites in the host by a female
Anopheles mosquito. Within minutes of biting, the motile sporozo-
ites join the liver and infect hepatocytes, where they further
differentiate into a replicative exo-erythrocytic form (EEF) that will
ultimately give rise to thousands of merozoites that initiate the
pathogenic erythrocytic cycle. Like other Apicomplexa parasites,
Plasmodium invades host target cells actively, using a parasite actin-
myosin motor machinery to translocate a junction formed between
parasite ligands and host cell receptors. This moving junction
results in the internalization of the parasite through an
invagination of the host cell plasma membrane, resulting in the
formation of the parasitophorous vacuole where the parasite
further develops [1–4]. The nature of the molecular interactions
mediating sporozoite invasion of hepatocyte still remains elusive.
Two well-characterized sporozoite surface proteins, the circum-
sporozoite protein and the thrombospondin-related adhesive
protein, are known to interact with the liver heparan sulphate
proteoglycans [5–7] which are responsible for the initial
sequestration of sporozoites in the liver sinusoids [8,9]. More
recently, two P. berghei proteins belonging to the Plasmodium 6-Cys
domain protein family and specifically produced in liver-infective
sporozoites, Pb36p and Pb36, were shown to be necessary for
sporozoite infection [10]. On the hepatocyte side, the only surface
protein known to play a key role in the infection by several
Plasmodium species is the tetraspanin CD81. Indeed, antibodies to
CD81 or CD81 silencing strongly reduce the infection of
hepatocytic cells by P. yoelii (a rodent parasite) and P. falciparum
(a human parasite) sporozoites. Additionally, P. yoelii sporozoites
fail to infect CD81-deficient mouse hepatocytes both in vitro and
in vivo [11–13]. Depending on the host target cell, another rodent
parasite, P. berghei, also uses CD81 for sporozoite invasion [14].
CD81 belongs to a family of proteins called tetraspanins which
have been implicated in various biological processes such as cell
adhesion, migration, cell fusion, co-stimulation, signal transduc-
tion, and differentiation (reviewed in [15–17]). They play a role in
the infection by several viruses including HIV and CD81 is
essential for the infection of hepatocytic cells by the hepatitis C
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HCV as it binds to HCV E2 envelope glycoprotein [18,19].
The molecular function of tetraspanins remains uncertain [15–
17]. Biochemical studies have shown that that tetraspanins
associate with many other surface molecules [20], and they have
been suggested to function as molecular organizers of membrane
multi-molecular complexes, collectively referred to as the ‘‘tetra-
spanin web’’ [21]. Within this network of interactions, tetraspanins
form primary complexes with a limited number of proteins called
tetraspanin partners. These tetraspanin/partner interactions are
direct and highly specific. For example, the tetraspanin CD151
associates directly with the integrins a6b1 and a3b1 and
functionally regulates these integrins [22,23]. CD9P-1 and EWI-
2, two related Ig domains proteins are direct partners of both CD9
and CD81, including in hepatocytes [24–27]. These primary
interactions resist to detergents such as digitonin (and in some
cases Triton X-100), and typically occur at a high stoichiometry
[22–27]. Tetraspanins also interact with one another, building
specific proteo-lipidic membrane microdomains to which they
probably target their partner proteins [15–17,28,29]. The
localization of CD81 in these microdomains is likely to be
important for the function of CD81 in sporozoite infection since
modulation of cellular cholesterol levels, that changes tetraspanin
microdomain organization, also modifies the extent of CD81-
dependent sporozoite invasion [13,29].
The molecular determinants of CD81 function in sporozoite
infection are not known. Tetraspanins have 4 transmembrane
domains that delimitate 3 short cytosolic regions and 2 extracellular
domains of unequal size (the small extracellular loop (SEL) and the
large extracellular loop (LEL)) [15–17]. The transmembrane
domains are the most conserved and are believed to contribute to
functions common to the different tetraspanins, possibly to the
interaction with one another and with lipids. The crystal structure of
CD81 LEL has been solved [30]. Two antiparallel a-helices (A and
E) in the continuity of the third and fourth transmembrane domains
form the stalk of the domain. The A helix is connected through a
short loop with a 3
rd helix (B) and molecular modelling indicates that
these 3 helices, although not conserved at the amino acid level, form
a structure common to all tetraspanins [31]. Two additional helices
(C and D), inserted in the stalk, contribute to form with the B helix
the head subdomainoftheLEL.Severalconserved cysteines,located
afterthe B helix (aCCG motifhallmarkoftetraspanins),betweenthe
C and D helices and at thebeginning of theE helix,contribute to the
maintenance of the LEL structure. Other tetraspanins have also a C
and D region, which are not structurally conserved [31]. The large
extracellular domain has been shown to be implicated in specific
tetraspanin functions. For example, the LEL of CD9, CD81 and
CD151 contribute to the interaction with EWI-2, CD19 and
integrins respectively [23,25,32]. In addition, the binding of the
HCV envelopeglycoprotein E2to CD81andthe function ofCD9 in
sperm-egg fusion critically depend on a Phe residue present in the D
region of the LEL [33,34].
TheaimofthisstudywastouncovertheresiduesofCD81thatare
critical for host cell infection by sporozoites. In a first phase of this
study, we used several CD9/CD81 chimeras, based on the fact that
although among tetraspanins CD9 is the closest to CD81, with 45%
identity at the amino acid level, it does not support Plasmodium
sporozoite invasion. The availability of the crystal structure made it
possible to generate inter-domain (or subdomain) swaps with
presumably minimal influence on the overall conformation of the
chimeric molecules. In a second step, following an analysis of CD81
crystal structure, and previous modelling studies [30,31], we
identified several residues of a solvent-exposed region that are
critical for infection. This is the first demonstration that residues of
the LEL located outside the C and D helices play a critical role in a
specific tetraspanin function. These findings have implications for
understanding the mechanisms of Plasmodium sporozoites invasion at
the molecular level as well as for the design of inhibitors specifically
targeting the CD81-dependent entry step.
Results
Critical role of CD81 LEL in P. yoelii sporozoite infection
HepG2-A16 cells express very little CD81 at their surface and are
not permissive to P. yoelii invasion. The few EEF observed were small
and intranuclear, resulting from CD81-independent sporozoite entry
through disruption of the cell plasma membrane [12]. We have
recently shown that stable expression of human CD81 is sufficient to
allow P. yoelii sporozoite entry and further differentiation into
replicative exo-erythrocytic forms (EEF) [13,14]. As shown in Fig. 1,
transient expression of CD81, but not of CD9, rendered HepG2-A16
cells susceptible to P. yoelii infection. This differential ability of CD81
and CD9 to support infection opened the way to investigating CD81
domains important for infection using CD9/CD81 chimeras. Two
previously characterized chimeras were first tested [35]. CD9681
consists of the first three transmembrane domains of CD9 joined to
the second half of CD81, comprising most of its large extracellular
domain (excluding the very first residues) and the fourth transmem-
brane region (Fig 1A). This chimera rendered HepG2-A16 cells
susceptible to P. yoelii infection while the reciprocal construction
CD8169 did not (Fig. 1B). This second chimera is known to be
functional since it potentiated the toxicity of the diphtheria toxin to
the same extent as CD9 [35]. Furthermore, a construct where CD9
LEL was exchanged with CD81 LEL (CD9LEL81) (Fig.1A) was also
able to support infection to the same extent as CD81 (Fig. 1B),
pointing out the importance of CD81 LEL.
The ability of CD81 to support P. yoelii sporozoite
infection depends on the first half of CD81 LEL
comprising the A and B helices
As swaps inside tetraspanin LEL abrogate the reactivity of most
mAbs [25] (and table I), all subsequent chimeric CD9/CD81
molecules and CD81 mutants were fused to EGFP to facilitate the
Author Summary
Minutes after the bite of a female mosquito, the malaria
parasite Plasmodium enters the liver where it invades liver-
specific cells called hepatocytes and undergoes one round
of multiplication. This stage is a prerequisite to the blood
stages of the life cycle which cause the malaria symptoms.
The invasion of hepatocytes probably requires a series of
interaction between the host cell and the parasite, but the
exact mechanisms are still elusive. CD81, a protein of the
tetraspanin superfamily, is the only hepatocyte surface
protein that has been shown to be strictly required for the
infection by the malaria parasite. We have here studied the
regions of CD81 that are important for infection, by
exchanging segments with the corresponding parts of a
closely related molecule, or by mutating discrete residues.
This study has uncovered a new functionally important
region of CD81 and, by comparing the ability of several
CD81 antibodies to block infection, has strengthened the
hypothesis that CD81 might regulate the function of
another molecule present at the hepatocyte surface during
Plasmodium infection. The region of CD81 identified here
is different from the region involved in the binding of the
hepatitis C virus.
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rendered HepG2-A16 cells permissive for infection when EGFP
was fused to their C-terminus (Fig 1C and data not shown),
indicating that the fusion with EGFP does not alter the function of
the molecules with respect to P. yoelii infection.
A molecule in which a swap between CD9 and CD81 was at the
CCG consensus site (CD9ccg81; the CCG motif immediately
follows the B helix, Fig. 1A) did not render HepG2-A16 cells
susceptible to infection (Fig. 1B), suggesting an important role of
the region comprising the A and B helices. Indeed, the reciprocal
chimera CD81ccg9 supported P. yoelii sporozoite infection after
transient transfection in HepG2-A16 cells (Fig. 1B–C), showing
that CD81 A and B helices in a CD9 backbone are sufficient to
confer HepG2-A16 cells the ability to support infection by P. yoelii
sporozoites. These results were obtained both with EGFP-tagged
constructs (Fig. 2) and non-tagged molecules (data not shown).
After transient transfection, the number of infected HepG2-A16
cells was significantly higher with CD81ccg9 than with CD9
Figure 1. The A and B helices of CD81 LEL confer CD9/CD81 chimeric molecules the ability to support infection by P. yoelii
sporozoites. A: Amino acid sequence alignment of CD81, CD9, and chimeras. Only the sequence of the LEL is shown. The origin of the flanking
domains (TM3 and TM4) is shown on both sides of the sequence. The position of CD81 helices is indicated on the top of the alignment. CD81 residues
are shown in red capital letters and CD9 residues in blue small letters. The CCG consensus site and other conserved cysteines, as well as a functionally
important site (VVDDD) are underlined. CD81 LEL residues presumably in contact with the SEL are indicated with an asterisk. Open circles shows
residues known to be involved in the interaction with HCV E2 glycoprotein. B and C: HepG2-A16 cells were transiently transfected with plasmids
expressing CD9, CD81, or CD81/CD9 chimeras and infected two days later with P. yoelii sporozoites. After two days incubation, the number of EEF-
infected cells was determined by immunofluorescence in triplicate wells. Results are expressed as mean6s.d. **, p,0.01 and *, p,0.05 as compared
to CD9-transfected cells.
doi:10.1371/journal.ppat.1000010.g001
Table 1. Recognition of CD81/CD9 chimeras by CD9 and CD81 mAbs.
Construct
Staining mAb CD81 CD9 CD9LEL81 CD9ccg81 CD81ccg9
CD9A-
81BCDE
CD9A’-
81BCDE CD81ABC-9DECD9[81A] CD9[81B]
EGFP 65 90 79 82 65 92 73 113 92 53
CD81 mAb 1D6 467 - 513 252 - 367 322 - - -
JS81 539 - 459 - - - - 51 - -
JS64 537 - 589 18 - 23 15 - - -
CD9 mAb 10B1 - 167 - - 193 - - 11 179 121
ALB-6 - 552 - - 64 - - - 178 -
The different chimeras in fusion with EGFP were transfected in Hepa1-6 cells, stained with the indicated mAbs and analyzed by flow-cytometry. The values correspond
to the mean fluorescence intensity in the FL1 channel (EGFP) or the FL2 channel, after subtraction of the value obtained with cells labelled only with the secondary
reagent. Other mAbs tested did not stain cells expressing any of the chimeras with swaps inside the LEL. These mAbs were TS81, 5A6, Z81, M38 (CD81); SYB-1, TS9, TS9b
(CD9). (-): no staining.
doi:10.1371/journal.ppat.1000010.t001
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ability of this chimera to support infection P. yoelii was
underestimated as a consequence of the low transfection efficiency
of these cells (,25%). Thus, to strengthen the conclusion that the
CD81 A and B helices in a CD9 backbone are sufficient to render
HepG2-A16 cells susceptible to infection, CD81ccg9 and
CD9ccg81 chimeras were stably expressed in HepG2-A16 cells
and compared to cells stably expressing CD81. As shown in
Fig. 2A, cells expressing CD9ccg81 were not infected by P. yoelii
sporozoites, in contrast to cells expressing CD81ccg9. The
infection rate of cells expressing CD81ccg9 was about half that
of CD81-expressing cells, despite a higher level of expression as
determined by flow-cytometry (data not shown). Fluorescence
microscopy showed that the cellular distribution of CD81ccg9 and
CD9ccg81 was indistinguishable from that of CD81 (Fig. 2B, 2C).
In addition, the parasite development was very similar in both cell
lines. (Fig. 2D).
The fact that the level of infection obtained after transfection of
CD81ccg9 was repeatedly lower than after CD81 transfection,
suggested that in addition to the A-B region, the second half of
CD81 LEL (comprising the C, D and E helices) may contribute to
CD81 function during Plasmodium infection. A chimera in which a
CD81/CD9 sequence switch was made just before the beginning
of the D helix (CD81ABC-9DE) (Fig. 1A) was as efficient as CD81
in supporting infection by P. yoelii sporozoites when expressed in
HepG2-A16 cells (Fig. 1B). This result indicates that CD81 D and
E helices do not play a specific role, and points to a possible role of
the C region. Two additional chimeras which restore 2 and 10
CD81 residues in the C region were constructed (CD81ABss9CDE
and CD81ABCp9DE). The level of infection in HepG2-A16 cells
expressing these constructs was intermediate between the levels
obtained after expression of CD81 and CD81ccg9, respectively
(Fig. 1C).
Residues at CD81 A–B junction are critical for P. yoelii
infection
The above data indicated that in a CD9 backbone, the A and B
helices of CD81 were necessary and sufficient to confer
susceptibility to P. yoelii infection. We used the crystal structure
of CD81 as well as published molecular modelling of tetraspanins
to guide site-directed mutagenesis [30,31,36]. We reasoned that if
CD81 plays a role as a receptor for a parasite protein, or as a
partner molecule for such receptor, residues critically involved in
these interactions would be solvent-exposed. We therefore
excluded from mutagenesis analysis residues that contribute to
the stability of the domain fold [30] or are buried in the molecule
[31]. Recently, Seigneuret proposed that the hydrophobic face of
CD81 LEL is in contact with the small extracellular loop [36], we
therefore also excluded residues predicted to be in contact with the
small domain from further analysis. Finally, since CD9 does not
support Plasmodium sporozoite infection, residues common to both
CD9 and CD81 were also not considered. From this analysis, we
uncovered a stretch of 14 amino acids located around CD81 A–B
helix junction, that are solvent-exposed and strongly different in
CD9 (Fig. 3A). Notably, the loop corresponding to the A–B
junction is highly acidic in CD81 with a row of 3 aspartic acids.
Each of the aspartate residues at A–B helix junction was
mutated to Alanine (Fig. 3B). Mutation of D137 reduced by more
than 60% the level of P. yoelii infection of transfected HepG2-A16
cells while the mutation of the two other D residues did not reduce
infection (Fig. 3B). These data suggested that D137 could be part
of a required site necessary for CD81 function during Plasmodium
infection. To test this, 2 triple mutants overlapping the D137
residue, VVD (135–137)RAAA and DDD (137–139)RAAA,
Figure 2. Reduced infection but normal schizont development
in HepG2-A16 cells stably expressing CD81ccg9 chimera. A:
HepG2-A16 cells stably expressing CD81, CD9, CD81ccg9 or CD9ccg81
(fused to EGFP) were infected with P. yoelii sporozoites. After two days
incubation, the number of EEF-infected cells was determined by
immunofluorescence in triplicate wells. Results are expressed as
mean6s.d. **, p,0.01 as compared to mock-transfected cells. B: The
localization of CD81 (fused to EGFP) stably expressed in HepG2-A16
cells was observed by fluorescence microscopy. Both the EGFP signal
(green) and the labeling with the CD81 mAb TS81 (red) are shown. A
merge image of the EGFP fluorescence and the mAb labeling is also
shown (bottom). C: Localization of CD9, CD81ccg9 or CD9ccg81 (fused
to EGFP) stably expressed in HepG2-A16. The images show the EGFP
signal. D: HepG2-A16 cells stably expressing CD81-EGFP (left) or
CD81ccg9-EGFP (right) were subjected to P. yoelii sporozoites infection.
After 2 days incubation, the cells were fixed and labeled. The images are
the merge of 3 different acquisitions: the green labeling corresponds to
the EGFP signal. The red labeling corresponds to the labeling with anti-
Plasmodium HSP70 antibodies and the blue labeling to DAPI
fluorescence. Bar=10 mm.
doi:10.1371/journal.ppat.1000010.g002
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the ability of CD81 to support P. yoelii infection in HepG2-A16
cells. In contrast, the mutations NN (141–142)RAA (Fig. 3C) or
AV (145–146)RET (not shown) had no effect on infection. All
mutants were recognized by most CD81 mAbs tested (see below)
and were expressed at cell surface to the same extent as WT CD81
in HepG2-A16 cells (data not shown) or in Hepa 1.6 cells (see
below). Replacement of all 3 aspartic acids by glutamic acids
(DDD (137–139)REEE) did not change the level of infection
indicating some tolerance in the length of the side chain provided
that the global charge was respected (Fig. 3C). The importance of
CD81 D137 is further confirmed by a mutant where CD81 DDD
(137–139) residues were replaced by the corresponding amino
acids of CD9 (CD81KDE) in CD9LEL81. Because substitution of
all D by E did not affect the function of CD81, the main change in
this mutant was the replacement of D137 by a lysine. As shown in
Fig. 3C, this mutant was completely non-functional with respect to
P. yoelii infection.
Hepatocytic cell permissiveness to Plasmodium infection
is conveyed by a short 21 residue CD81 region
Additional chimeras were generated to determine whether other
CD81 residues in either the A or the B helix contribute to the
ability of CD81 to support infection by P. yoelii sporozoites (Fig. 4).
In these chimeras, swaps between CD9 and CD81 were made
nearby the A–B junction (Fig. 4A). A CD9/CD81 chimera
(CD9A-81BCDE) where the sequence switch was made immedi-
ately before D138 was not functional (Fig. 4B). This was expected
since in this chimera D137 was replaced by the corresponding K
residue in CD9. The chimera in which the sequence switch was
made 3 residues before the predicted end of the A helix (before the
VVD sequence in CD81: CD9A’-81BCDE) was on the contrary
completely functional (Fig. 4B). Altogether these results confirm
the importance of CD81 D137 residue and indicate that except for
the last 3 residues, the A helix of CD81 can be replaced by that of
CD9 without altering the ability to support P. yoelii infection.
A chimera in which CD9 A helix was replaced by that of CD81
(CD9[81A]) was not functional (Fig. 4B). In this chimera, the five
CD81 residues (VVDDD (135–139)) the contribution of which has
been demonstrated by site-directed mutagenesis (see above) are
conserved (Fig. 4A), except D139 which is replaced by a
functionally equivalent glutamic acid. This result, together with
the fact that the chimera CD81ccg9 is partly functional, suggested
that in addition to these 5 amino acids, other residues, located in
the B region, contributed to the ability of CD81 to support
Plasmodium infection of hepatocytic cells. Indeed, a chimera in
Figure 3. Mutations of residues at the A-B helix junction impair the ability of CD81 to support infection by P. yoelii sporozoites. A:
Alignment of human CD81, mouse CD81 and human CD9. Residues that contribute to the stability of the subunit fold as reported by Kitadokoro et al.
[30] are boxed in red. Additional residues that are buried according to the modelling of Seigneuret et al. [31] are boxed in pink. Some of the buried
residues are also involved in the stabilization of the molecule and are therefore boxed in red. Residues potentially in contact with the small
extracellular domain, according to the modelling of Seigneuret [36] and not fitting in the previous categories, are in blue. Finally, additional residues
identical in both CD9 and CD81 sequences are in parma. The different mutants are also indicated on this alignment. The multiple mutants are
designed as follow: VVD: VVD (135–137)RAAA; DDD: DDD (137–139)RAAA; NN: NN (141–142)RAA; EEE: DDD (137–139)REEE; KDE: DDD (137–
139)RKDE B and C: HepG2-A16 cells were transfected with the indicated mutants 48 hours before infection with P. yoelii sporozoites. After two days
incubation, the number of EEF-infected cells in triplicate wells was determined by immunofluorescence. Results are expressed as mean6s.d. B: single
mutations. **, p,0.01 as compared to cells transfected with WT CD81. C: triple or double mutations. **, p,0.01 as compared to mock-transfected cells
doi:10.1371/journal.ppat.1000010.g003
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substituted by the 21 corresponding residues of CD81 (CD9[81B]:
VVDDDANNAKAVVKTFHETLD) could support infection by
P. yoelii sporozoites to the same extent as CD81ccg9 (Fig. 4B).
Again, because the transfection efficiency in HepG2-A16 cells is
low, the ability of CD9[81B] to support infection was more evident
in HepG2-A16 cells stably expressing this chimera (Fig. 4C).
The same CD81 determinants are required in a murine
model
To check that the above results were not HepG2-A16 cell
specific, we tested whether CD81 structural requirements were the
same in the murine cell line Hepa1-6. This cell line expresses
mCD81 and is permissive to P. yoelii infection. Treatment with an
anti mouse CD81 mAb (MT81) prevents infection by this parasite
[13] (Fig. 5). When cells are transfected with hCD81, they remain
susceptible to infection despite MT81 treatment because the anti-
mouse CD81 mAb does not recognize hCD81 (which can
functionally replace mCD81 in this model [13]) (Fig. 5). These
cells therefore represent an alternative model to study the
molecular determinants of CD81 that play a role in the infection
of hepatocytic cells by P. yoelii sporozoites.
As shown in Fig. 5, the chimeras CD9LEL81 and CD9A’-
81BCDE that fully supported P. yoelii infection in HepG2-A16 cells
restored the level of infection of MT81-treated Hepa1.6 cells to the
initial level, as did hCD81. As in HepG2-A16 cells, CD81ccg9 and
CD9[81B] partially restored infection. In contrast, hCD9, CD9A-
81BCDE and CD9[81A] did not restore infection. In addition,
The mutants VVD (135–137)RAAA and DDD (137–139)RAAA
were unable to restore infection in MT81-treated Hepa1.6 cells
(data not shown). Altogether, these data confirm the role of the 21-
residues region comprising the A–B junction and the B helix.
Expression of chimeras at cell surface and recognition by
CD9 and CD81 mAbs
The EGFP signal obtained with the different constructs was
reasonably similar after transfection in Hepa1.6 (table I) or
Figure 4. 21 residues of CD81 in a CD9 backbone are sufficient to render hepatocytic cells susceptible to P. yoelii sporozoites
infection. A: Amino acid sequence alignment of CD9, CD81 and chimeras. Only the sequence of the large extracellular loop of the different chimeras
is shown. The origin of the flanking domains (TM3 and TM4) is shown on both sides of the sequence. The position of CD81 helices are indicated on
the top of the alignment. CD81 residues are shown in red capital letters and CD9 residues in blue small letters. The CCG consensus site and other
conserved cysteines, as well as a functionally important site (VVDDD) are underlined B: HepG2-A16 cells were transiently transfected with plasmids
expressing CD9, CD81, or CD81/CD9 chimeras and infected two days later with P. yoelii sporozoites. After two days incubation, the number of EEF-
infected cells in triplicate wells was determined by immunofluorescence. Results are expressed as mean6s.d. **, p,0.01 as compared to mock-
transfected cells. C: HepG2-A16 cells stably expressing CD81, CD9, CD81ccg9 or CD9[81B] were infected with P. yoelii sporozoites. After two days
incubation, the number of EEF-infected cells was determined in triplicate wells by immunofluorescence. Results are expressed as mean6s.d. **,
p,0.01 as compared to mock-transfected cells.
doi:10.1371/journal.ppat.1000010.g004
Figure 5. The same determinants are involved in a murine
model. Hepa1-6 cells were transfected with the indicated plasmids
24 hours before infection with P. yoelii sporozoites in the presence of
the anti-mouse CD81 mAb MT81 as indicated. The number of EEF-
infected cells (mean6s.d.) was determined as described in the Materials
and Methods section. **, p,0.01 as compared to MT81-treated, mock-
transfected cells.
doi:10.1371/journal.ppat.1000010.g005
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different chimeras by a panel of 7 CD81 mAbs and 5 CD9 mAbs
was tested after transfection in the murine hepatoma cell line Hepa
1.6 because the level of transfection is higher in this cell line that in
HepG2-A16 cells (and thus the observed variations are more
reliable), and because the high level of human CD9 in HepG2-
A16 cells precluded the analysis with CD9 mAb.
The localization at cell surface of all constructs tested but one
(CD81ABC-9DE) could be verified by labelling with certain CD9
or CD81 mAbs and flow-cytometry analysis. So far, all tetraspanin
mAbs were shown to recognize the LEL [15]. Accordingly,
CD9LEL81 was recognized by all CD81 mAb tested here (TS81,
5A6, Z81, M38, JS64, JS81, 1D6: table I). CD9681 and CD8169
have previously been shown to be recognized by CD81 and CD9
mAbs respectively [35].
Most mAbs tested here (TS81, 5A6, Z81, and M38 to CD81;
SYB-1, TS9 and TS9b to CD9) failed to recognize chimeras with
swaps inside the LEL (although in CD81LEL9, CD8169 and
CD9681 the exchange between CD9 and CD81 is engineered a
few residues after the predicted beginning of the LEL, these
constructs are not considered here as molecules with a swap inside
the LEL) (data not shown). The CD81 mAb JS64 and JS81, as well
as the CD9 mAb ALB-6 could stain cells expressing certain
chimeras, but at a much reduced level as compared to cells
expressing WT CD81 or CD9 (table I). The mAb 1D6 is unique
for its ability to recognize in ELISA assay a peptide corresponding
to CD81 amino acids 179–193, encompassing the D helix and a
few adjacent residues [33]. Accordingly, this mAb was found to
recognize all constructs conserving CD81 D helix including
CD9ccg81 and CD9A-81BCDE (Table I). Using 1D6, we could
demonstrate that these two chimeras were expressed at a level
similar to that of CD81 in transfected HepG2-A16 cells (data not
shown), indicating that the lack of infection after transfection of
these chimeras is not due to diminished surface expression.
Additionally, 10B1 was described as the only CD9 mAb that
recognizes a CD82/CD9 chimera in which the swap was done at
the CCG consensus sequence [25]. This is consistent with its
ability to recognize CD81ccg9, CD9[81A] and CD9[81B]
(Table I). Importantly, the staining of cells expressing the
functional chimera CD9[81B] is lower than the staining of cells
expressing the non-functional chimeras CD81ccg9 and CD9[81A]
(Table I). Thus the lack of activity of CD81ccg9 and CD9[81A] is
not due to a lack of surface expression.
A CD81 mAb recognizing the A–B junction does not
block infection by P. yoelii sporozoites
The surface expression and the conformation of the CD81
mutants unable to support infection by P. yoelii sporozoites were
tested. Hepa1.6 cells were transiently transfected with the different
constructs and surface expression was assessed by flow-cytometry,
using a panel of 7 CD81 mAbs produced in the mouse (Fig. 6A).
Most anti-tetraspanin mAbs if not all do not recognize the
denatured (reduced) protein indicating the recognition of confor-
mational epitopes. This is confirmed by our analysis of chimeric
CD9/CD81 molecules with swaps in the LEL, which were not
recognized (or only at a low level) by all CD9 or CD81 mAbs
except by mAb 10B1 to CD9 and 1D6 to CD81, both able to
recognize the CDE region of the corresponding tetraspanin
(Table I). All mutants were recognized by 6 CD81 mAbs with a
staining very similar to the staining of WT CD81, therefore
indicating a correct conformation. Interestingly, 5A6 had a ,70%
reduction of binding to the VVD (135–137)RAAA mutant. The
fact that 5A6 was the only CD81 mAb to have a reduced ability to
bind to this mutant indicates that the epitope recognized by this
mAb critically depends on residues located at the A–B junction.
This is coherent with the second Val being substituted by a Met in
mouse CD81, which is not recognized by the mAb (Fig. 3A).
We then tested whether 5A6 could inhibit the infection of
HepG2-A16 cells stably expressing CD81 by P. yoelii sporozoites.
All CD81 mAbs tested here almost completely inhibited infection
at 25 mg/ml, except 5A6 which had no effect on infection at
concentrations up to 100 mg/ml (Fig. 6B). This is not due to a
lower affinity of 5A6 mAb (data nor shown).
The CD81 VVD (135–137)RAAA and DDD (137–
139)RAAA mutants associate with CD9P-1 and EWI-2
The two major CD81 partners identified so far in hepatocytic
cells are CD9P-1 and EWI-2, two Ig domain molecules [25].
Because tetraspanins have been shown in some cases to modulate
the function of the proteins to which they associate, it was
important to check whether the mutants unable to support
infection by P. yoelii sporozoites still associate with these molecules.
CHO cells were transfected with CD9P-1 or EWI-2 and either
WT CD81, the VVD (135–137)RAAA mutant or the DDD(137–
139)RAAA mutant (all in fusion with EGFP), and their
interactions was tested by immunoprecipitation after cell lysis
with digitonin (a detergent suitable to visualize direct interactions
within the tetraspanin web). In preliminary experiments TS81 was
Figure 6. A CD81 mAb binds poorly to the non-functional
mutant VVD (135–137)RAAA but does not block infection. A:
Hepa 1–6 cells were transfected with the indicated construct in pEGFP-
N3 and analyzed for the surface expression and recognition of the
transgene by several CD81 mAb using flow-cytometry analysis. Data are
expressed as mean fluorescence intensity. In this experiment, the
antibodies were used at 20 mg/ml (JS64, M38, JS81) or at 1/100 ascitic
fluid dilution (all other mAbs). B: HepG2-A16/CD81 cells were infected
with P. yoelii sporozoites in the presence of the indicated mAbs at
25 mg/ml except when otherwise indicated. All mAbs are directed to
CD81 except TS9 which is a CD9 mAb and does not inhibit P. yoelii
infection.
doi:10.1371/journal.ppat.1000010.g006
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expressed by CHO cells, while 1D6 did not, so 1D6 was used for
further analysis. As shown in fig 7, CD9P-1 and EWI-2 were co-
immunoprecipitated with WT CD81 and the two CD81 mutants,
and reciprocally the CD81 mutants were co-immunoprecipitated
with CD9P-1 and EWI-2. This shows that the inability of the two
mutants to support infection by P. yoelii sporozoites is not due to a
loss of interaction with these partner molecules and further
indicates that these mutants have a correct conformation.
Mutants of the SEL b-sheet are not functional
Our initial data, using CD9681 and CD9LEL81 chimeras,
indicated that CD81 SEL could be replaced with that of CD9
without affecting the ability to support P. yoelii sporozoites infection
(Fig. 1). Both CD9 and CD81 SEL are predicted to contain a b-
sheet that was proposed to tightly interact with the LEL [36]. To
further investigate the role of the SEL, residues of this b-sheet were
mutated to Ala. Two mutants were designed: SEL-CD81, in which
NLLYLE (43–48) was mutated to AAAAAA in the hCD81
molecule, and SEL-CD9LEL81, in which TKSIFEQ (41–47) was
mutated to AAAAAAA in the CD9LEL81 chimeric molecule
(Fig. 8A). None was able to confer cell susceptibility to P. yoelii
infection (Fig. 8B). These mutants are normally expressed at the
cell surface as shown by the binding of the non-conformational
mAb 1D6 (Fig. 8C). Five out of 7 CD81 mAb tested showed a
reduced binding to cells expressing this mutant as compared to
cells expressing WT CD81, indicating that the conformation of the
LEL of these mutants is modified (Fig. 8C).
Discussion
The molecular mechanisms underlying Plasmodium sporozoite
invasion of hepatocytes remain poorly characterized [1–4]. So far,
only one host molecule, the tetraspanin CD81, has been shown to
play a crucial role in the infection by several Plasmodium species,
including P. falciparum, the deadliest human parasite [11–14]. In
Figure 7. The VVD (135–137)RAAA and DDD (137–139)RAAA
mutants unable to support infection by P. yoelii sporozoites
interact with CD9P-1 and EWI-2. CHO cells were transiently
transfected with WT or mutant CD81 plasmids (in pEGFP-N3), together
with a CD9P-1 (top) or a EWI-2 (bottom) cDNA. After 48 h, the cells were
lysed with digitonin and immunoprecipitations with antibodies against
CD81, CD9P-1 and EWI-2 were performed. After electrophoresis and
transfer, the membranes were incubated with biotin-labelled mAbs to
CD81 (TS81), CD9P-1 (1F11) and EWI-2 (8A12). The mutants are
designed as follows: VVD: VVD (135–137)RAAA; DDD: DDD (137–
139)RAAA
doi:10.1371/journal.ppat.1000010.g007
Figure 8. Mutation of the SEL b-sheet abolishes P. yoelii
infection and alters the LEL conformation. A: Sequence of CD81
and CD9 SEL, and description of the SEL mutants. The boxes indicate
the b-sheet [36]. B: HepG2-A16 cells were transiently transfected with
plasmids expressing CD9, CD81, or CD81 molecules with mutations in
the SEL, and infected two days later with P. yoelii sporozoites. After two
days incubation, the number of EEF-infected cells was determined by
immunofluorescence in triplicate wells. Results are expressed as
mean6s.d. **, p,0.01 as compared to mock-transfected cells. C: Hepa
1–6 cells were transfected with the indicated constructs and analyzed
for the surface expression of the transgene by flow-cytometry analysis.
Data are expressed as mean fluorescence intensity. In this experiment,
the antibodies were used at 20 mg/ml (JS64, M38, JS81) or at 1/100
ascitic fluid dilution (all other mAbs).
doi:10.1371/journal.ppat.1000010.g008
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are critical for the ability of CD81 to confer hepatocyte
permissiveness to Plasmodium sporozoites. We have delineated a
stretch of 21 amino acids, starting from the end of the A helix to
the end of the B helix, that are sufficient, when present in a CD9
backbone, to render hepatocytic cells permissive to infection. Site-
directed mutagenesis in this region has highlighted the crucial role
of D137 and adjacent residues. This is the first demonstration that
this region of CD81 (and other tetraspanins) is functionally
important in a physiological or pathological process.
CD81 LEL domains and residues required for hepatocyte
permissiveness to Plasmodium infection
So far specific tetraspanin functions have been linked to residues
in the LEL. Only few studies have investigated whether the A–B
region contributes to tetraspanin specific functions. This region
was found not to directly contribute to the interaction of CD9 with
EWI-2 or CD9P-1 ([25]; S. Charrin and E. Rubinstein,
unpublished data) and replacement of most of this region did
not prevent the interaction of CD151 with the integrin a3b1 [37].
In contrast, our results indicate that the A–B region of CD81 on a
CD9 backbone is sufficient to allow infection of hepatocytic cells
by P. yoelii sporozoites. More specifically, a major part of the A
helix can be replaced by the corresponding region of CD9 without
altering sporozoite infection, and substitution of 21 amino acids of
CD9 consisting of the end of the A helix and the B helix with the
corresponding residues of CD81 yielded a chimera that supports
to some extent infection by P. yoelii sporozoites. The key role of
some residues was demonstrated by site-directed mutagenesis.
Importantly, these residues were first selected after an analysis of
CD81 3D structure [30,31,36], looking for residues that were
solvent-exposed (Fig. 3A, Fig. 9). Among these solvent-exposed
residues, D137 plays a key role since its mutation together with
adjacent residues completely abolished the ability of CD81 to
support P. yoelii infection, despite normal surface expression and
conformation as determined by the recognition by several
conformation-dependent mAbs and the ability to interact with
CD9P-1 and EWI-2.
We have demonstrated that a chimeric molecule in which a
swap between CD81 and CD9 was done immediately before D
helix (CD81ABC-9DE) was completely functional with respect to
Plasmodium sporozoite infection (Fig. 1). The D regions of CD9 and
CD81 are completely different both in structure and amino acid
sequence [15,31], excluding the possibility that the D region of
CD9 could functionally replace that of CD81. Thus the D region
of CD81 does not play a direct role in the entry of Plasmodium
sporozoites. This is consistent with the fact that both human and
murine CD81 molecules support P. yoelii sporozoite infection
[13](and this study), despite the fact that the D region is the most
divergent region of mouse and human CD81 molecules (only 59%
conservation, 66% similarity). This observation contrasts with
most previous studies, if not all, that have pointed to a critical role
for residues in the D domain for specific tetraspanin functions.
Thus, a triple mutation in the D region of CD9 abolishes its
activity in gamete fusion and another one prevents CD151
interaction with the integrins a3b1 and a6b1, as well as the ability
of these integrins to support cellular cable formation in matrigel
[34,38]. Two residues in the D domain are also essential for the
ability of CD9 to upregulate the binding of diphtheria toxin to its
receptor, the transmembrane precursor of Heparin-Binding EGF
[39].
The CD9/CD81 chimeras containing CD81 B helix but in
which the C helix was that of CD9 (CD81ccg9 and CD9[81B])
had a reduced ability to support infection by P. yoelii sporozoites as
compared to WT CD81. This may suggest that this region of
CD81, although not essential, contributes to the function of CD81
during infection. However, two CD81/CD9 chimeras that
progressively restored CD81 residues in the C regions progres-
sively restored the ability to support P. yoelii invasion (Fig 1C),
suggesting an indirect role for this region. The folding of the LEL
brings the C helix in proximity to the A–B junction and almost on
the top of the B helix (see Fig. 9). The CD9 C helix is 4 amino
acids shorter than that of CD81 and is predicted to form a b strand
instead of a a helix [31]. It is therefore possible that the C region of
CD9 folds in a way that hampers the interaction of key residues at
the A–B junction or in the B helix with other proteins.
Possible mechanisms through which CD81 may support
Plasmodium infection
How CD81 allows entry of Plasmodium sporozoites into
hepatocytic cells is still unknown. In one hypothesis, CD81 would
serve as a receptor for a sporozoite protein. However, several data
are not consistent with this model. First, a recombinant CD81
LEL fused with GST did not block infection of hepatocytes by
sporozoites, and did not bind to sporozoites [11], while a similar
protein inhibited HCV infection, probably by interacting with the
HCV E2 envelope glycoprotein, a CD81 ligand [40–42].
Additionally, we have shown here that the loop separating the A
Figure 9. 3D structure of CD81 LEL. The drawing of CD81 LEL (PDB
#1g8q) was generated in MolMol. Four helices (A, C, D, E) are drawn in
red while the B helix, crucial for P. yoelii infection is displayed in blue.
The black balls indicate the CCG ubiquitous motif. The crucial D137 as
well as D138 and D139 are in purple while V135 and V136 are in royal
blue. Residues V146, T149, F150, T153 and L154 putatively involved in
contact with the SEL are indicated in dark blue. T163, F186 and D196
residues, in yellow, have been reported to play a role in the HCV E2
glycoprotein binding to CD81-LEL. Residues V135, V136, T163, F186 and
D196 projected backward, behind the drawing plane. The two disulfides
bridges are colored light coral. Hydrophilic residues K144, K148 and
E152 located on the top of the B helix are in green. The SEL, in cyan, is in
front of the drawing plane.
doi:10.1371/journal.ppat.1000010.g009
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during P. yoelii sporozoite infection (Fig. 3). If CD81 was a receptor
for a sporozoite protein, it would be expected that mAbs that
require this region for the recognition of CD81 are the most potent
at inhibiting infection. This is not the case since the only mAb
(5A6) that requires this critical site for maximum binding does not
block infection, in contrast to all other CD81 mAbs (Fig. 6).
Another hypothesis is that CD81 modulates the activity of a
molecule to which it associates, that could function as a sporozoite
receptor. This hypothesis is based on the ability of tetraspanins to
interact with many other integral proteins, and to functionally
modulate these proteins [15–17]. For example, the expression of
CD9 increases by several orders of magnitude the ability of
diphtheria toxin to bind to its receptor, the transmembrane
precursor of Heparin-Binding EGF [35,43]. In this hypothesis, not
all CD81 molecules but only those that associate with this
particular molecular partner would be functionally competent for
infection. If CD81 A–B junction participates in the interaction
with such a partner protein, mutations in this region may abolish
the interaction of CD81 with this partner, and as a result may
prevent Plasmodium sporozoite entry. Furthermore, this association
could conceal the A–B region and therefore mAbs such as 5A6
that require this region for optimal binding would not recognize
the CD81 molecules present in this CD81-partner complex.
Because only this subset of CD81 molecules would play a role in
the infection by Plasmodium sporozoites, this model explains why
5A6, which is the only mAb that requires CD81 A–B region for
binding is also the only mAb that fails to inhibit P. yoelii and P.
falciparum sporozoite infection. The identification of an anti-
tetraspanin mAb that fails to recognize particular complexes is not
unprecedented. Indeed, a CD151 mAb fails to recognize the
fraction of CD151 molecules associated with integrins because its
epitope overlaps the integrin-binding site [22,38]. Thus, the
inability of 5A6 to inhibit infection while interacting with a critical
region of CD81 is consistent with the hypothesis that CD81
functions through the regulation of an associated protein.
If 5A6 fails to recognize a pool of CD81 associated with a
particular partner molecule, one would expect to observe
differences in the pattern of proteins co-immunoprecipitated with
CD81 using 5A6 or other CD81 mAb. So far we have found that
5A6 and TS81 immunoprecipitates collected after cell lysis with
digitonin, a detergent appropriate to visualize primary complexes
within the tetraspanin web, were very similar (data not shown).
However, this finding does not preclude the hypothesis that 5A6
fails to recognize a fraction of CD81 associated with a particular
partner, because digitonin probably dissociates certain primary
complexes [25]. The major known CD81 partners in hepatocytes
are CD9P-1 and EWI-2, and the mutations DDD (137–139)R
AAA and VVD (135–137)RAAA that abrogate CD81 activity in
sporozoite infection did not alter its capacity to associate with these
two molecules. This finding strongly suggests that the interaction
of CD81 with these molecules does not play a direct role in the
infection by Plasmodium sporozoites. Efforts to identify additional
CD81 partner molecules will provide insights into the mechanisms
by which CD81 supports infection by Plasmodium sporozoites.
CD81 SEL stabilizes the conformation of the large
extracellular loop
The SEL of most tetraspanins has a conserved secondary
structure, namely a small predicted b-strand flanked by non
regular structure stretches [36]. We have mutated the residues of
this b-strand to Ala in CD81 and in a chimera in which the CD9
LEL was exchanged with that of CD81 (CD9LEL81). Both
mutants were expressed at cell surface similarly to WT CD81, as
determined by the staining with a conformation-independent
mAb, 1D6. This contrasts with a previous study in which a CD81
mutant with substitution of the SEL with a linker was partially
retained intracellularly [44]. Thus, CD81 SEL b-sheet does not
contribute to the transport of CD81 to the cell surface.
The two SEL mutants do not support P. yoelii sporozoite
infection. It is unlikely that the SEL directly participates to the
interaction with a parasite ligand or with a partner molecule since
chimeras in which the SEL and the LEL are respectively that of
CD9 and CD81 (CD9681 and CD9LEL81) are functional,
despite the fact that the sequences of CD9 and CD81 SEL are
highly divergent. We have shown that the two SEL mutants have
an altered conformation as shown by the reduction of binding of 5
CD81 mAbs out of 7 tested. These data suggest that the SEL helps
stabilizing the LEL active conformation. They are consistent with
molecular modelling predicting that the small hydrophobic SEL b-
strand packs in a conserved hydrophobic groove of the LEL [36].
Most of the LEL residues that are in contact with the SEL in the
modeled CD81 structure are either size or polarity-conserved, or
both, in CD9 (M. Seigneuret, personal communication). There-
fore, it is probable that the LEL groove of CD81 can
accommodate the CD9-SEL (and vice versa).
Comparison of CD81 mechanism of action in HCV and
Plasmodium infection
CD81 is essential for the infection of hepatocytic cells not only
by several Plasmodium species, but also by the hepatitis C virus [19].
The wide distribution of CD81 suggests that CD81 expression is
not the sole determinant of HCV and Plasmodium sporozoite tissue
tropism. The tight junction protein Claudin-1 was recently shown
to be required for HCV entry and to contribute to the virus
tropism [45], but it is not necessary for P. yoelii invasion (Yalaoui. S
et al; unpublished data). CD81 LEL is critical for the ability of
CD81 to confer susceptibility to HCV glycoprotein-mediated
infection [46]. The mutation of residues that are different in the
human protein and in CD81 proteins from uninfectable species, as
well as random mutagenesis, pointed to the key role of residues in
the C and D helices for the binding of CD81 to the HCV envelope
glycoprotein E2 [33,46–48]. A hydrophobic Phe residue present in
the D helix is in particular essential for the interaction of CD81
with the HCV envelope glycoprotein E2 in vitro [33,46–48],
although the importance of this residue during HCV infection is
controversial [46,48]. We have in contrast excluded a role for the
D region during P. yoelii infection and highlighted a role for the AB
helix junction and the B helix. Interestingly, the B helix and the
residues that have been implicated in E2 binding are on different
sides of CD81 (Fig. 9). Our data indicate additional differences in
the mechanisms by which CD81 supports Plasmodium and HCV
infections. Indeed, the CD81 mAb 5A6 is efficient in blocking the
binding of the HCV envelope protein E2 to CD81 [49] and HCV
infection [41,50,51]. We therefore predict that if a CD81 partner
interacting through the A–B junction is shown to play a key role
during the infection by malaria sporozoites, it will not play a
crucial role during HCV infection.
Materials and Methods
Antibodies
Several mAb used in this study were generated in our laboratory
and were described elsewhere [13,20,21,24,25]. These include
TS81 specific for hCD81; SYB-1, ALB-6, 10B1, TS9 and TS9b
specific for hCD9; 1F11 and 8A12 that respectively recognize
CD9P-1 and EWI-2; MT81 is a rat an anti-mouse CD81. 5A6 and
1D6, two anti-hCD81 were kindly provided by Dr. S. Levy [33].
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and Dr. F. Lanza [53], respectively. JS64 was purchased from
Beckman-Coulter (Marseille, France) and JS81 from BD biosci-
ences (San Jose, CA).
Construction of CD9/CD81 chimeric molecules and
mutagenesis
The plasmids encoding CD81, CD9, CD9P-1 and EWI-2, as
well as the chimeras CD9681 and CD8169 have been previously
described [24,25,35]. Additional constructs were engineered by
classical PCR protocols using overlapping oligonucleotides. The
constructs were inserted into pcDNA3 (Invitrogen, Cergy
Pontoise, France) and/or pEGFP-N3 (Clontech, Mountain view,
CA) to make EGFP fusion proteins. The human CD81 was
mutated using the QuickChangeTM site-directed mutagenesis kit
from Stratagene (Amsterdam, The Netherlands), according to the
manufacturer’s specifications, except for the design of primers
which was done according to the method of Zheng et al. [54].
Cells, transfection and generation of stably transfected
cell lines
The human hepatocarcinoma cell line HepG2-A16 [55], the
mouse hepatoma cell line Hepa1-6 (ATCC CRL-1830) and CHO
(Chinese Hamster Ovary) cells were cultured in DMEM (Invitro-
gen) supplemented with 10% FCS (Biowest, Nuaille ´, France),
2 mM glutamine and antibiotics.
For infection, HepG2-A16 and Hepa1-6 cells were seeded in 8-
chamber plastic Lab-Tek slides (10
5 cells) (Nalge Nunc Interna-
tional, Cergy Pontoise, France) or in 96 wells microplate
(2610
4 cells) 24 h hours before transfection. Cells were transfect-
ed using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions and infections were done two days
later. For generation of stable HepG2-A16-transfectants, pEGFP-
N3 constructs were linearised by digestion with Afl III and
EcoO109I restriction enzymes and cleaned up using the QIAquick
PCR purification kit (Qiagen) before transfection. G418 (Gibco)
was added to cells 2 days later at the concentration of 1 mg/ml.
After a 3-week selection period, EGFP expressing cells were sorted
using a FACS-VANTAGE-DIVA (Becton-Dickinson-BDIS). The
cells expressing CD81, CD81ccg9, CD9ccg81 and CD9 were
further cloned by limiting dilution.
Parasites and invasion assay
Plasmodium infection into HepG2-A16 and MT81-treated
Hepa1-6 were performed as described before [12,14]. P. yoelii
(265BY strain) sporozoites were obtained from dissection of
infected Anopheles stephensi mosquito salivary glands. For infection,
the cells were inoculated with 10
5 P. yoelii sporozoites in 8 wells
Lab-Tek culture chambers (Nalge Nunc International, Cergy
Pontoise, France) or 2610
4 sporozoites in 96 wells culture plates.
After 3 h at 37uC, cultures were washed and further incubated in
fresh medium for 36 h before fixation and parasite labelling using
an antibody again Plasmodium heat shock protein 70 (HSP70) [11].
Quantification of infected cells in triplicate wells was done either
under fluorescence microscope (Lab-Tek) or by using the Odyssey
Infrared Imaging System (LI-COR Biosciences) as described
previously [56]. For antibody inhibition assays, the mAbs were
added at a concentration of 25 mg/ml (unless otherwise specified)
at the same time as the parasites. The results are expressed as
mean number of EEF/well +/- SD. The data were analysed for
statistical significance using the OneWay ANOVA followed by the
Tukey multiple comparison test.
Immunofluorescence analysis
For flow cytometric analysis, cells were detached using a non-
enzymatic solution (Invitrogen), washed and stained with primary
mAbs. After 3 washes in culture medium, cells were incubated
with 10 mg/ml PE-labeled secondary antibody (Beckman Coulter)
and washed again three times. All incubations were performed for
30 minutes at 4uC. Analysis of cell-surface staining was performed
using a FACSscan flow cytometer (Becton-Dickinson, San Jose,
CA, USA) using appropriate compensations.
Immunoprecipitation and western blotting
CHO cells were electroporated as described previously [25].
The cells were lysed 48 h later in 30 mM Tris, pH 7.4, 150 mM
NaCl, 0.02% NaN3, protease inhibitors and 1% digitonin (high
purity; Calbiochem, San Diego, CA, USA). Immunoprecipitations
were then performed as described previously [24,25]. The
composition of the different immunoprecipitates was analyzed by
western-blotting using biotin-labelled mAbs.
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